Evogene Reports Q2 and First Half 2026 Results Amid Activist Board Fight
EVGN sits 51% above its 52-week low of $0.37 on light trading volume (0.2× avg).
Summary
Evogene reported second quarter and first half 2026 financial results. The company posted a second quarter loss per share of 67 cents and revenue of $681,000. The results come amid an ongoing activist board battle and a highly dilutive ATM offering. The market will focus on revenue trajectory and cash burn given the company's small market cap and going concern risks. This follows the Q1 loss of $5.87 million and revenue of $0.334 million reported in May.
At the time of this announcement, EVGN was trading at $0.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.8M. The 52-week trading range was $0.37 to $1.50. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.